Skip to main content
SENATE 920117th CongressCommittee on Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security. Hearings held. With printed Hearing: S.Hrg. 117-176.

Affordable and Safe Prescription Drug Importation Act

Last Action
3/23/2021

Actions

  • 2021-03-23Committee on Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security. Hearings held. With printed Hearing: S.Hrg. 117-176.
  • 2021-03-23Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • 2021-03-23Introduced in Senate

CRS Summary

As of 2021-03-23 (00)

Affordable and Safe Prescription Drug Importation Act

This bill allows expanded importation of eligible prescription drugs and addresses related issues.

Current law allows the Department of Health and Human Services (HHS) to authorize the importation of certain eligible prescription drugs from Canada if HHS certifies to Congress that doing so would pose no additional risk to public health and safety and would result in significant cost savings for consumers. The bill removes this certification requirement and requires HHS to issue regulations that permit the importation of qualifying prescription drugs from Canada. After a certain amount of time, HHS may authorize importation from certain other countries if it determines that importation from Canada has resulted in cost savings for consumers and increased access to safe medication.

The bill also expands the types of prescription drugs eligible for importation to include, for example, biologics such as insulin.

Furthermore, the bill allows individuals to use an eligible licensed foreign pharmacy to fill a U.S.-issued prescription for a qualifying drug for personal use. Currently, an individual seeking to import a prescription drug generally must acquire a waiver from HHS.

The bill imposes various requirements related to certification of foreign sellers, labeling of imported drugs, and supply chain security.

The bill also (1) prohibits certain acts that discriminate against foreign sellers, such as charging higher prices to foreign sellers than to other sellers in the same country; and (2) imposes criminal penalties for online websites that sell counterfeit drugs or dispense drugs without a required prescription.

Cosponsors (20)

  • Cory Booker (D-NJ)
  • Bob Casey (D-PA)
  • Tammy Baldwin (D-WI)
  • Richard Blumenthal (D-CT)
  • Sherrod Brown (D-OH)
  • Kirsten Gillibrand (D-NY)
  • Martin Heinrich (D-NM)
  • Angus King (I-ME)
  • Amy Klobuchar (D-MN)
  • Patrick Leahy (D-VT)
  • Joseph Manchin (D-WV)
  • Jeff Merkley (D-OR)
  • Alex Padilla (D-CA)
  • John Reed (D-RI)
  • Jeanne Shaheen (D-NH)
  • Tina Smith (D-MN)
  • Debbie Stabenow (D-MI)
  • Chris Van Hollen (D-MD)
  • Elizabeth Warren (D-MA)
  • Sheldon Whitehouse (D-RI)

Subjects

  • Administrative law and regulatory procedures
  • Canada
  • Congressional oversight
  • Department of Health and Human Services
  • Drug safety, medical device, and laboratory regulation
  • Government information and archives
  • Government studies and investigations
  • Prescription drugs
  • Trade restrictions
  • User charges and fees
Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.